| Biological consequences of MHC-II expression by tumor cells in cancer ML Axelrod, RS Cook, DB Johnson, JM Balko Clinical cancer research 25 (8), 2392-2402, 2019 | 331 | 2019 |
| Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial R Rajasingham, AS Bangdiwala, MR Nicol, CP Skipper, KA Pastick, ... Clinical Infectious Diseases 72 (11), e835-e843, 2021 | 167 | 2021 |
| A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention SC Wei, WC Meijers, ML Axelrod, NAAS Anang, EM Screever, ... Cancer discovery 11 (3), 614-625, 2021 | 165 | 2021 |
| T cells specific for α-myosin drive immunotherapy-related myocarditis ML Axelrod, WC Meijers, EM Screever, J Qin, MG Carroll, X Sun, ... Nature 611 (7937), 818-826, 2022 | 109 | 2022 |
| Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19 SM Lofgren, MR Nicol, AS Bangdiwala, KA Pastick, EC Okafor, ... Open forum infectious diseases 7 (11), ofaa500, 2020 | 58 | 2020 |
| Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer ML Axelrod, MJ Nixon, PI Gonzalez-Ericsson, RE Bergman, MA Pilkinton, ... Clinical Cancer Research 26 (21), 5668-5681, 2020 | 49 | 2020 |
| Emerging biomarkers for cancer immunotherapy in melanoma ML Axelrod, DB Johnson, JM Balko Seminars in cancer biology 52, 207-215, 2018 | 48 | 2018 |
| Tumor-specific major histocompatibility-II expression predicts benefit to anti–PD-1/L1 therapy in patients with HER2-negative primary breast cancer PI Gonzalez-Ericsson, JD Wulfkhule, RI Gallagher, X Sun, ML Axelrod, ... Clinical Cancer Research 27 (19), 5299-5306, 2021 | 41 | 2021 |
| Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate JL Schwartz-Roberts, KL Cook, C Chen, AN Shajahan-Haq, M Axelrod, ... Cancer research 75 (6), 1046-1055, 2015 | 35 | 2015 |
| MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression DA Franklin, JL James, ML Axelrod, JM Balko Cancer Drug Resistance 3 (3), 603, 2020 | 22 | 2020 |
| Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen … SA Dabydeen, K Kang, ES Díaz-Cruz, A Alamri, ML Axelrod, KB Bouker, ... Carcinogenesis 36 (1), 122-132, 2015 | 20 | 2015 |
| Progesterone promotes immunomodulation and tumor development in the murine mammary gland LR Werner, KA Gibson, ML Goodman, DE Helm, KR Walter, SM Holloran, ... Journal for Immunotherapy of Cancer 9 (5), 2021 | 18 | 2021 |
| RNA-sequencing reveals a distinct transcriptomic signature for giant cell myocarditis and identifies novel druggable targets K Amancherla, J Qin, Y Wang, ML Axelrod, JM Balko, KH Schlendorf, ... Circulation research 129 (3), 451-453, 2021 | 5 | 2021 |
| Novel mechanism in cardiac injury: Immune checkpoints EM Screever, ML Axelrod, MA Blair, DZ Trykall, JV Barnett, DM Roden, ... European Heart Journal 41 (Supplement_2), ehaa946. 3625, 2020 | 3 | 2020 |
| Peripheral T-cell receptor repertoire dynamics in small cell lung cancer ML Balbach, ML Axelrod, JM Balko, A Bankhead, T Shaffer, L Lim, J Guo, ... Translational Lung Cancer Research 12 (2), 257, 2023 | 2 | 2023 |
| Peripheral blood monocyte abundance predicts outcomes in patients with breast cancer ML Axelrod, Y Wang, Y Xu, X Sun, CA Bejan, PI Gonzalez-Ericsson, ... Cancer research communications 2 (5), 286-292, 2022 | 2 | 2022 |
| Cytotoxic T cells specific for alpha-myosin drive immunotherapy related myocarditis J Balko, M Axelrod, W Meijers, E Screever, MG Carroll, X Sun, E Tannous, ... | 2 | 2022 |
| 812 Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells X Sun, M Axelrod, Y Wang, V Sanchez, P Gonzalez-Ericsson, D Johnson, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), A848-A848, 2021 | 1 | 2021 |
| Abstract PD9-06: Peripheral blood gene signatures predict response to neoadjuvant chemotherapy in breast cancer patients ML Axelrod, PI Gonzalez-Ericsson, X Sun, RE Bergman, J Donaldson, ... Cancer Research 81 (4_Supplement), PD9-06-PD9-06, 2021 | 1 | 2021 |
| Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance (vol 11, e007736, 2023) JL James, BC Taylor, ML Axelrod JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024 | | 2024 |
Justin M. BalkoProfessor of Medicine, and Pathology, Microbiology, and Immunology, Vanderbilt UniversityVerified email at vumc.org
